Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MAP2K1 L98_K104delinsQ |
Therapy | MK2206 |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 L98_K104delinsQ | Advanced Solid Tumor | resistant | MK2206 | Preclinical - Cell culture | Actionable | In a preclinical study, MK2206 treatment failed to inhibit activation of Mek and Erk in human cells expressing MAP2K1 L98_K104delinsQ in culture (PMID: 29768711). | 29768711 |
PubMed Id | Reference Title | Details |
---|---|---|
(29768711) | Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis. | Full reference... |